Vivos Therapeutics, Inc. ((VVOS)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivos Therapeutics, Inc. recently held its earnings call, revealing a mix of optimism and challenges. The company reported strong revenue growth and strategic moves to expand its market presence through acquisitions and alliances. However, increased operational costs and a net loss present hurdles. Despite these challenges, Vivos remains optimistic about its new business model and future revenue potential.
Significant Revenue Growth
In the third quarter of 2025, Vivos Therapeutics experienced a remarkable 76% increase in revenue, totaling $6.8 million compared to $3.9 million in Q3 2024. This growth also represented a 78% sequential increase from the second quarter of 2025, showcasing the company’s robust financial performance.
Impact of SCN Acquisition
The acquisition of the Sleep Center of Nevada (SCN) played a crucial role in boosting revenue. It contributed $2.2 million from OSA sleep testing services and an additional $1.3 million from new treatment centers, underscoring the strategic value of this acquisition.
New Business Model Success
Vivos’ pivot to a new business model, focusing on the acquisition of sleep medical practices, is yielding positive results. This strategic shift is expected to enhance the company’s performance in the coming quarters, aligning with their growth objectives.
High Demand for Vivos Treatment
The demand for Vivos treatment remains high, with approximately two-thirds of SCN patients choosing it over alternatives. The average case value exceeds $5,000, highlighting the treatment’s perceived value and effectiveness.
Increased Costs and Net Loss
Despite revenue growth, Vivos faced increased general and administrative expenses, which rose by approximately $5.7 million or 42% to $19.2 million. This contributed to a net loss of $5.4 million in Q3 and $14.3 million for the first three quarters of 2025.
Cash Flow Challenges
The company encountered cash flow challenges, using $1.7 million more in cash for operations and $5.5 million more in investing activities during the first nine months of 2025 compared to 2024. These challenges were largely due to acquisition costs.
Forward-Looking Guidance
During the earnings call, Vivos announced a notable 76% increase in revenue, driven by the SCN acquisition and strategic alliances. Despite a $5.4 million net loss in Q3, the company expressed confidence in the growth trajectory and potential profitability of their new business model. Vivos highlighted a shift from their legacy model, with decreased reliance on VIP enrollment revenue, and projected further growth as they expand their market presence and optimize operational efficiencies.
In summary, Vivos Therapeutics’ earnings call painted a picture of strong revenue growth and strategic expansion efforts, tempered by increased costs and net loss challenges. The company’s optimism about its new business model and future potential remains a key takeaway, as they continue to navigate the complexities of the evolving market landscape.